Skip to content

Released Mar 17, 2021, after the close

10-K filed Mar 18, 2021, 77 days after period end · 0001564590-21-013945

Q4 2020 · 10-K
Revenue$8.28M−26.8% vs Q4 2019−53.6% vs Q3 2020
Net Income-$59.54MN/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$1.48N/M vs Q4 2019N/M vs Q3 2020
Operating Incomederived-$24,843,000N/M
Operating Cash Flowderived-$18,879,000N/M
Margins · derived
Operating margin-300.1%−169.4 pt vs Q4 2019
Net margin-719.3%−588.5 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020Q4 2019Q4 2018Q4 2017
Revenue$8.28M$11.31M$19.09M$4.04M
Net Income-$59.54M-$14.79M-$1.49M-$15.34M
EPS Diluted-$1.48-$0.65-$0.07-$33.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR